| Title: |
P-2145. Low Prevalence of Cytomegalovirus Infections Beyond Two Years after Solid Organ Transplant: An Opportunity for Diagnostic Stewardship |
| Authors: |
Heldman, Madeleine R; Maziarz, Eileen K; Saullo, Jennifer; Tam, Patrick C; Kothadia, Sonya; Seidenfeld, Amanda; Arif, Sana; Steinbrink, Julie M; Sim, Beatrice; Huggins, Jonathan; Ellis, Matthew; Devore, Adam; Lerman, Joseph; Segovia, M Christina; McElroy, Lisa; Wolfe, Cameron R; Alexander, Barbara D; Baker, Arthur W |
| Source: |
Open Forum Infectious Diseases ; volume 13, issue Supplement_1 ; ISSN 2328-8957 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2026 |
| Description: |
Background Solid organ transplant (SOT) recipients frequently undergo cytomegalovirus (CMV) PCR testing throughout their post-transplant course. While CMV infections are common early (< 2 years) after SOT, the prevalence of CMV infections beyond 2 years has not been reported.Figure 1:CMV PCR testing and CMV DNAemia beyond two years after transplant in solid organ transplant recipients who survived to two yearsTable 1:Solid organ transplant recipients who underwent CMV PCR testing at least once beyond two years after transplanta) Chi squared and Fisher exact tests were used for categorical variables and the Mann-Whitney U test was used for continuous variables.b) Heart includes 3 heart-liver recipients and 21 heart-kidney recipients. Kidney includes 61 kidney-pancreas recipients. Liver includes 54 liver-kidney recipients. Intestine includes 4 intestine-liver-pancreas recipients. Methods We performed a single center retrospective study to determine the period prevalence of CMV PCR testing, CMV DNAemia, and CMV disease beyond 2 years after non-lung SOT. All non-lung, adult SOT recipients (SOTR) who underwent their first SOT between 2/24/14-8/1/22 and who survived through 2 years were included. Patients were followed until death, re-transplant, or 8/1/24 (whichever came first). CMV DNAemia was defined as any plasma CMV load ≥ 450 IU/mL, which was a common threshold to initiate preemptive CMV therapy at our institution. CMV PCRs were performed for evaluation of symptoms of CMV disease or as asymptomatic screening at clinician discretion. Patients did not receive CMV prophylaxis beyond 6 months, except for the 30-days following treatment with lymphodepleting antibodies for rejection.Figure 2:Solid organ transplant recipients with CMV infections beyond two years after transplanta) All cases of CMV disease in D+R- and D-R- consisted of CMV syndrome.b ) This seropositive recipient (R+) was an intestine-liver-pancreas recipient who developed proven CMV enteritis involving the small bowel allograft within ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/ofid/ofaf695.2308 |
| Availability: |
https://doi.org/10.1093/ofid/ofaf695.2308; https://academic.oup.com/ofid/article-pdf/13/Supplement_1/ofaf695.2308/66356656/ofaf695.2308.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.DBBA7402 |
| Database: |
BASE |